Does neoadjuvant therapy improve survival in pancreatic adenocarcinoma?
作者信息
Chopra Asmita, Paniccia Alessandro
机构信息
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
出版信息
Hepatobiliary Surg Nutr. 2021 Oct;10(5):728-730. doi: 10.21037/hbsn-21-250.
Abstract
摘要
相似文献
1
Does neoadjuvant therapy improve survival in pancreatic adenocarcinoma?新辅助治疗能否提高胰腺腺癌患者的生存率？
Hepatobiliary Surg Nutr. 2021 Oct;10(5):728-730. doi: 10.21037/hbsn-21-250.
2
Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.新辅助治疗后中性粒细胞与淋巴细胞比值升高与临界可切除性胰腺导管腺癌切除术后较差的生存率相关。
Surgery. 2016 Nov;160(5):1288-1293. doi: 10.1016/j.surg.2016.04.039. Epub 2016 Jul 20.
3
Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.新辅助化疗后胰十二指肠切除术治疗早期胰腺腺癌患者的设施量-生存关系。
Surgery. 2021 Jul;170(1):207-214. doi: 10.1016/j.surg.2020.12.003. Epub 2021 Jan 14.
4
Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.新辅助治疗与直接手术治疗可切除胰腺腺癌的对比：一项全国性倾向评分匹配分析。
Surgery. 2017 Mar;161(3):592-601. doi: 10.1016/j.surg.2016.08.040. Epub 2016 Oct 27.
5
Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.新辅助治疗对非转移性胰腺导管腺癌患者生存获益的影响：倾向评分匹配和意向治疗分析。
J Surg Oncol. 2019 Nov;120(6):976-984. doi: 10.1002/jso.25681. Epub 2019 Aug 26.
6
Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.在现代时代，新辅助放化疗联合多药新辅助化疗治疗 II-III 期可切除胰腺腺癌与改善病理结果和生存相关。
Am Surg. 2021 Sep;87(9):1386-1395. doi: 10.1177/00031348211038581. Epub 2021 Aug 12.
7
Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.新辅助治疗与可切除胰腺腺癌的生存改善相关。
Cancer. 2011 May 15;117(10):2044-9. doi: 10.1002/cncr.25763. Epub 2010 Nov 18.
8
Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.新辅助治疗对胰腺腺癌切除术后局部复发的影响。
J Am Coll Surg. 2008 Mar;206(3):451-7. doi: 10.1016/j.jamcollsurg.2007.10.002. Epub 2007 Dec 27.
9
Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.与先行手术及辅助化疗相比，接受新辅助化疗的III期胰腺腺癌患者总生存期有所延长：一项基于美国国立癌症数据库的意向性分析。
Surgery. 2016 Oct;160(4):1080-1096. doi: 10.1016/j.surg.2016.06.010. Epub 2016 Aug 10.
10
Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma.可切除及边界可切除胰腺腺癌新辅助放化疗联合或不联合全身化疗的疗效
Front Oncol. 2020 Sep 16;10:1461. doi: 10.3389/fonc.2020.01461. eCollection 2020.
引用本文的文献
1
Synthetic magnetic resonance imaging predicts the prognostic evaluation of rectal cancer.合成磁共振成像预测直肠癌的预后评估。
Quant Imaging Med Surg. 2023 Mar 1;13(3):2026-2028. doi: 10.21037/qims-22-624. Epub 2022 Oct 19.
2
The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"?全身治疗时代胰腺癌的管理策略——“手术优先”还是“手术最后”？
Hepatobiliary Surg Nutr. 2022 Aug;11(4):597-600. doi: 10.21037/hbsn-22-146.
本文引用的文献
1
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.可切除胰腺腺癌围手术期化疗的疗效：一项 2 期随机临床试验。
JAMA Oncol. 2021 Mar 1;7(3):421-427. doi: 10.1001/jamaoncol.2020.7328.
2
FOLFIRINOX Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines.基于 FOLFIRINOX 和吉西他滨的疗法治疗胰腺导管腺癌：源自患者源性细胞系的经验教训。
Anticancer Res. 2020 Jul;40(7):3659-3667. doi: 10.21873/anticanres.14355.
3
Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer.对于局限性胰腺癌，不进行放疗的全身治疗可能适合作为新辅助治疗。
Hepatobiliary Surg Nutr. 2020 Jun;9(3):296-303. doi: 10.21037/hbsn.2019.04.17.
4
Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.血清 CA19-9 对新辅助治疗的反应可预测胰腺腺癌的肿瘤大小缩小和生存。
Ann Surg Oncol. 2020 Jun;27(6):2007-2014. doi: 10.1245/s10434-019-08156-3. Epub 2020 Jan 2.
5
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.胰腺癌切除术后放化疗与单纯化疗的随机试验。
N Engl J Med. 2004 Mar 18;350(12):1200-10. doi: 10.1056/NEJMoa032295.
Zotero 插件